Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02616393 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study of Study of Tesevatinib in Subjects With NSCLC and Brain or Leptomeningeal Metastases
A Phase 2 study of Non-Small Cell Lung Cancer and Brain Metastases, sponsored by Kadmon Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
- 7
- Study locations
NCT02616393 is a Phase 2 study of Non-Small Cell Lung Cancer and Brain Metastases that has completed, run by Kadmon Corporation. The registered enrollment target is 36 participants, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (95% lower). The trial reports 7 study locations across 5 states.
The verdict
NCT02616393, a Phase 2 study of Non-Small Cell Lung Cancer and Brain Metastases, has completed, sponsored by Kadmon Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
- 7
- Study locations
Study Summary
A study to assess the activity of tesevatinib in subjects with non-small cell lung cancer (NSCLC) and activating epidermal growth factor receptor (EGFR) mutations who have disease progression with Brain Metastases (BM) or Leptomeningeal Metastases (LM) or who have either BM or LM at initial presentation (IP)
Conditions Studied
Interventions
- DRUG Tesevatinib
Study Locations (7)
California
- Beverly Hills Cancer Center - Beverly Hills
- USC Norris Oncology/Hematology Newport Beach - Newport Beach
- John Wayne Cancer Institute - Santa Monica
Colorado
- University of Colorado Cancer Center - Aurora
District of Columbia
- Georgetown University Medical Center - Washington D.C.
Tennessee
- Sarah Cannon Research Institute - Nashville
Texas
- UT M.D. Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2015-11 |
| Est. Completion | 2018-04-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02616393
The ClinicalTrials.gov registry entry for NCT02616393 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (95% lower). The listed sponsor is Kadmon Corporation, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which Tesevatinib is the first listed.
NCT02616393 reports 7 study locations spanning 5 distinct geographic areas - top geographies include California, Colorado, District of Columbia.
Frequently Asked Questions
What is clinical trial NCT02616393 about?
NCT02616393 is a clinical study titled "Phase 2 Study of Study of Tesevatinib in Subjects With NSCLC and Brain or Leptomeningeal Metastases". A study to assess the activity of tesevatinib in subjects with non-small cell lung cancer (NSCLC) and activating epidermal growth factor receptor (EGFR) mutations who have disease progression with Brain Metastases (BM) or Leptomeningeal Metastases (LM) or who have either BM or LM at initial presenta...
What is the current status of trial NCT02616393?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2015-11. Estimated completion is 2018-04-03.
What conditions does trial NCT02616393 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Brain Metastases, Leptomeningeal Metastases.
What interventions are being tested in trial NCT02616393?
The interventions under investigation include: Tesevatinib (DRUG).
Who is sponsoring clinical trial NCT02616393?
This trial is sponsored by Kadmon Corporation, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02616393 being conducted?
This trial has 7 study locations across California, Colorado, District of Columbia, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
RECRUITING · Phase 2
-
A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.